Quantumzyme Corp. has reported its financial performance for the fiscal year ending July 31, 2025, revealing no revenue generated during the period, consistent with the previous fiscal year. The company incurred operating expenses of $180,537, an increase from $163,593 in the prior year, primarily due to higher professional fees. Additionally, other expenses rose to $18,732 from $14,976, attributed to increased interest expenses from additional debt. Consequently, Quantumzyme recorded a net loss of $199,269, compared to a net loss of $178,569 in the previous year.
The company, which focuses on engineered enzymes for clean and green chemistry applications, has not yet commercialized its products. As of the reporting date, Quantumzyme has developed its first enzyme for the production of Ibuprofen, targeting pharmaceutical companies that manufacture generic drugs. The company is currently in discussions with third-party manufacturers and distributors to facilitate large-scale production and distribution of this enzyme. However, it has not filed for patent protection for this product, citing that the costs associated with patent prosecution currently outweigh the anticipated benefits.
Operationally, Quantumzyme remains in the development stage, with a single employee overseeing all aspects of the business. The company has expressed intentions to expand its workforce as it progresses with its business model. As of July 31, 2025, Quantumzyme reported total current assets of $584 against total current liabilities of $441,302, resulting in a working capital deficit of $440,718. The company has indicated that its future operations depend heavily on securing additional funding, either through the sale of securities or strategic partnerships.
Looking ahead, Quantumzyme acknowledges the challenges it faces, including the need for substantial capital to support its operations and growth. The company has highlighted the importance of establishing strategic partnerships to enhance its market position and drive revenue generation. However, it remains uncertain about its ability to secure necessary funding on favorable terms, which could significantly impact its business continuity and growth prospects. The management has indicated that without sufficient financing, the company may need to curtail its development plans, potentially affecting its ability to achieve commercial success.
About Quantumzyme Corp.
Reliant Service Inc. is a development-stage company that previously provided office file cabinet distribution services, sourcing products from Chinese manufacturers for the U.S. market. It operates as a shell company with no current assets or operations, focusing on growth through acquisitions. Its core activities include office equipment sales, revenue recognition from U.S. customers, and managing financial and regulatory compliance.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.